Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

ClinicalTrials.gov ID: NCT03823391

Public ClinicalTrials.gov record NCT03823391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.

Study identification

NCT ID
NCT03823391
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
48 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 26, 2019
Primary completion
Apr 7, 2020
Completion
Aug 25, 2020
Last update posted
Jul 18, 2021

2019 – 2020

United States locations

U.S. sites
18
U.S. states
11
U.S. cities
18
Facility City State ZIP Site status
Rheum Assoc of North Alabama /ID# 213626 Huntsville Alabama 35801
AZ Arthritis and Rheum Researc /ID# 208515 Phoenix Arizona 85032
C.V. Mehta MD, Med Corporation /ID# 213068 Hemet California 92543
Robin K. Dore MD, Inc /ID# 213045 Tustin California 92780
Inland Rheum & Osteo Med Grp /ID# 213044 Upland California 91786
Suncoast Clinical Research /ID# 213973 New Port Richey Florida 34652
Arthritis Center, Inc. /ID# 213972 Palm Harbor Florida 34684
W. Broward Rheum Assoc Inc. /ID# 211017 Tamarac Florida 33321
BayCare Medical Group, Inc. /ID# 213935 Tampa Florida 33614-7101
Institute of Arthritis Researc /ID# 213043 Idaho Falls Idaho 83404
PRN Professional Research Network of Kansas, LLC /ID# 213046 Wichita Kansas 67205
Clinvest Research LLC /ID# 215451 Springfield Missouri 65810-2607
Duke Early Phase Research Unit (DCRI) /ID# 213212 Durham North Carolina 27710
Paramount Medical Research Con /ID# 209042 Middleburg Heights Ohio 44130
STAT Research, Inc. /ID# 213933 Vandalia Ohio 45377-9464
West Tennessee Research Inst /ID# 208838 Jackson Tennessee 38305
PCCR Solution /ID# 215457 Colleyville Texas 76034
Trinity Universal Research Association /ID# 209167 Plano Texas 75024-5283

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03823391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2021 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03823391 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →